Clearpoint Neuro is trading 5.25% down at $10.91, with no new company announcement explaining the October 6 decline.

  • The latest listed release was its August 3 second-quarter results.
  • In the supplied market context, major indexes were up more than 0.5%, so broad-market weakness does not explain the move.
  • Recent coverage linked the sharp September 29 selloff to partner uniQure’s AMT-130 trial data, but did not establish it as this session’s cause.